MonoSol Rx to develop scheduled drugs in easy-to-swallow film format
MonoSol Rx has initiated DEA registration of its Tennessee development facility and its Indiana manufacturing facility for Class II-V scheduled drugs, where it hopes to develop films containing scheduled drugs for patients that cannot swallow tablets easily.
MonoSol Rx has initiated DEA registration of its Tennessee development facility and its Indiana manufacturing facility for Class II-V scheduled drugs, where it hopes to develop films containing scheduled drugs for patients that cannot swallow tablets easily.
MonoSol Rx's ceo, P. Scott Bening said: 'This registration was required by increasing demand from pharmaceutical companies interested in scheduled drugs, including the pain category, to be placed in quick-dissolving film for oral delivery. Quick dissolving film enables dose administration for individuals who are compromised by severe pain and have difficulty swallowing conventional tablets.'
MonoSol Rx, headquartered in Portage, Indiana, uses film as a fast-dissolve oral drug delivery technology, based on technology it acquired from Kosmos Pharma.
Its FDTAB film oral dosage form looks like a postage stamp and dissolves readily on the tongue to deliver drugs to a patient, replacing the use of conventional tablets and capsules. MonoSol Rx also employs its proprietary film technology on a range of veterinary and nutraceutical products.